These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 26643220)
1. 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. Boechat Fda C; Sacramento CQ; Cunha AC; Sagrillo FS; Nogueira CM; Fintelman-Rodrigues N; Santos-Filho O; Riscado CS; Forezi Lda S; Faro LV; Brozeguini L; Marques IP; Ferreira VF; Souza TM; de Souza MC Bioorg Med Chem; 2015 Dec; 23(24):7777-84. PubMed ID: 26643220 [TBL] [Abstract][Full Text] [Related]
2. Neuraminidase from Influenza A and B Viruses is Susceptible to the Compound 4-(4-Phenyl-1H-1,2,3-Triazol-1-yl)-2,2,6,6-Tetramethylpiperidine-1- Oxyl. Sacramento CQ; Jordão AK; Abrantes JL; Alves CM; Marttorelli A; Fintelman-Rodrigues N; de Freitas CS; de Melo GR; Cunha AC; Ferreira VF; Souza TML Curr Top Med Chem; 2020; 20(2):132-139. PubMed ID: 31880262 [TBL] [Abstract][Full Text] [Related]
3. [Sensitivity of the epidemic and pandemic influenza virus strains to zanamivir (Relenze) in in vitro experiments]. L'vov DK; Burtseva EI; Galegov GA; Beliakova NV; Shevchenko ES; Kolobukhina LV; Merkulova LN; Prilipov AG; Leneva IA; Baranov NI; Gorelikov VN; Abramov DD Vopr Virusol; 2010; 55(6):10-4. PubMed ID: 21381333 [TBL] [Abstract][Full Text] [Related]
4. The Path of Least Resistance: Mechanisms to Reduce Influenza's Sensitivity to Oseltamivir. Phillips AM; Shoulders MD J Mol Biol; 2016 Feb; 428(3):533-537. PubMed ID: 26748011 [No Abstract] [Full Text] [Related]
5. Oseltamivir analogues bearing N-substituted guanidines as potent neuraminidase inhibitors. Mooney CA; Johnson SA; 't Hart P; Quarles van Ufford L; de Haan CA; Moret EE; Martin NI J Med Chem; 2014 Apr; 57(7):3154-60. PubMed ID: 24649802 [TBL] [Abstract][Full Text] [Related]
6. Influenza virus susceptibility and resistance to oseltamivir. Aoki FY; Boivin G; Roberts N Antivir Ther; 2007; 12(4 Pt B):603-16. PubMed ID: 17944268 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Gubareva LV; Webster RG; Hayden FG Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315 [TBL] [Abstract][Full Text] [Related]
8. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir. Wang D; Sleeman K; Huang W; Nguyen HT; Levine M; Cheng Y; Li X; Tan M; Xing X; Xu X; Klimov AI; Gubareva LV; Shu Y Antiviral Res; 2013 Mar; 97(3):240-4. PubMed ID: 23267831 [TBL] [Abstract][Full Text] [Related]
9. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia. Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516 [TBL] [Abstract][Full Text] [Related]
10. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. Farrukee R; Mosse J; Hurt AC Expert Rev Anti Infect Ther; 2013 Nov; 11(11):1135-45. PubMed ID: 24093683 [TBL] [Abstract][Full Text] [Related]
11. [Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza]. Reina J Rev Esp Quimioter; 2006 Dec; 19(4):317-22. PubMed ID: 17235399 [No Abstract] [Full Text] [Related]
12. Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay. Eichelberger MC; Hassantoufighi A; Wu M; Li M Virol J; 2008 Sep; 5():109. PubMed ID: 18822145 [TBL] [Abstract][Full Text] [Related]
13. Antivirals and influenza: frequency of resistance. Monto AS Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S110-2. PubMed ID: 18820569 [TBL] [Abstract][Full Text] [Related]
14. Dextran sulfate-resistant A/Puerto Rico/8/34 influenza virus is associated with the emergence of specific mutations in the neuraminidase glycoprotein. Yamada H; Nagao C; Haredy AM; Mori Y; Mizuguchi K; Yamanishi K; Okamoto S Antiviral Res; 2014 Nov; 111():69-77. PubMed ID: 25234090 [TBL] [Abstract][Full Text] [Related]
15. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Carr S; Ilyushina NA; Franks J; Adderson EE; Caniza M; Govorkova EA; Webster RG Pediatr Infect Dis J; 2011 Apr; 30(4):284-8. PubMed ID: 21048522 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and anti-influenza viral activities of 1,3-diarylprop-2-en-1-ones: a novel class of neuraminidase inhibitors. Kinger M; Park YD; Park JH; Hur MG; Jeong HJ; Park SJ; Lee WS; Kim SW; Yang SD Arch Pharm Res; 2012 Mar; 35(4):633-8. PubMed ID: 22553055 [TBL] [Abstract][Full Text] [Related]
17. Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant. Zhang J; Murugan NA; Tian Y; Bertagnin C; Fang Z; Kang D; Kong X; Jia H; Sun Z; Jia R; Gao P; Poongavanam V; Loregian A; Xu W; Ma X; Ding X; Huang B; Zhan P; Liu X J Med Chem; 2018 Nov; 61(22):9976-9999. PubMed ID: 30365885 [TBL] [Abstract][Full Text] [Related]
18. John F. Enders lecture 2006: antivirals for influenza. Ong AK; Hayden FG J Infect Dis; 2007 Jul; 196(2):181-90. PubMed ID: 17570104 [TBL] [Abstract][Full Text] [Related]
19. Zanamivir. A potent and selective inhibitor of influenza A and B viruses. Aoki FY; Hayden FG Clin Pharmacokinet; 1999; 36 Suppl 1():v-ix. PubMed ID: 10429834 [No Abstract] [Full Text] [Related]
20. Baloxavir marboxil (Xofluza) for treatment of influenza. Med Lett Drugs Ther; 2018 Dec; 60(1561):193-196. PubMed ID: 30653474 [No Abstract] [Full Text] [Related] [Next] [New Search]